Literature DB >> 15649562

Metabolism and antiviral activity of ribavirin.

William B Parker1.   

Abstract

Thirty years after its synthesis, the mechanism of action of ribavirin is still not completely understood. Although much is known about the metabolism and biochemical effects of ribavirin in human cells, there is still much to be learned about the precise mechanism of action of ribavirin with the various viruses. New information about its ability to induce mutations in viral genomes has led to new questions about its mechanism of action. There is considerable evidence that indicates that ribavirin triphosphate (RTP) can interact with the various viral RNA polymerases, and it seems likely that this interaction is important to the mechanism of action of ribavirin. It seems likely that ribavirin will not have one universal mechanism of action, but will inhibit different viruses in different ways. In some cases, inhibition of IMP dehydrogenase may be sufficient for antiviral activity. Whereas, in other cases, inhibition of viral RNA polymerases by RTP may be more important. It is also likely that RTP will interact with the different viral RNA polymerases in different ways leading to different mechanisms of actions. More comprehensive studies are needed that address all aspects of ribavirin metabolism and biochemical actions to gain a thorough understanding of the activity of this agent. Finally, the differences in the metabolism and biochemical actions of ribavirin, selenazofurin, and tiazofurin indicate that small structural changes can have profound effects on biological activity. This observation is well known by investigators familiar with nucleoside analogs, but indicate that one should not assume that agents of similar structure have identical activities.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15649562     DOI: 10.1016/j.virusres.2004.11.006

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  78 in total

Review 1.  The application and mechanism of action of ribavirin in therapy of hepatitis C.

Authors:  Emmanuel Thomas; Marc G Ghany; T Jake Liang
Journal:  Antivir Chem Chemother       Date:  2012-09-25

Review 2.  Novel approaches in anti-arenaviral drug development.

Authors:  Andrew M Lee; Antonella Pasquato; Stefan Kunz
Journal:  Virology       Date:  2010-12-22       Impact factor: 3.616

3.  Mutagenesis-induced, large fitness variations with an invariant arenavirus consensus genomic nucleotide sequence.

Authors:  Ana Grande-Pérez; Gema Gómez-Mariano; Pedro R Lowenstein; Esteban Domingo
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

Review 4.  IMP dehydrogenase: structure, mechanism, and inhibition.

Authors:  Lizbeth Hedstrom
Journal:  Chem Rev       Date:  2009-07       Impact factor: 60.622

5.  Identification of Clotrimazole Derivatives as Specific Inhibitors of Arenavirus Fusion.

Authors:  Sylvia Rothenberger; Christian Widmann; Stefan Kunz; Giulia Torriani; Evgeniya Trofimenko; Jennifer Mayor; Chiara Fedeli; Hector Moreno; Sébastien Michel; Mathieu Heulot; Nadja Chevalier; Gert Zimmer; Neeta Shrestha; Philippe Plattet; Olivier Engler
Journal:  J Virol       Date:  2019-03-05       Impact factor: 5.103

6.  Biochemical impact of the host adaptation-associated PB2 E627K mutation on the temperature-dependent RNA synthesis kinetics of influenza A virus polymerase complex.

Authors:  Shilpa Aggarwal; Stephen Dewhurst; Toru Takimoto; Baek Kim
Journal:  J Biol Chem       Date:  2011-08-04       Impact factor: 5.157

Review 7.  Phytotoxicity and Other Adverse Effects on the In Vitro Shoot Cultures Caused by Virus Elimination Treatments: Reasons and Solutions.

Authors:  Katalin Magyar-Tábori; Nóra Mendler-Drienyovszki; Alexandra Hanász; László Zsombik; Judit Dobránszki
Journal:  Plants (Basel)       Date:  2021-03-31

8.  T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro.

Authors:  Tatiana Baranovich; Sook-San Wong; Jianling Armstrong; Henju Marjuki; Richard J Webby; Robert G Webster; Elena A Govorkova
Journal:  J Virol       Date:  2013-01-16       Impact factor: 5.103

9.  Intracellular effects of the Hepatitis C virus nucleoside polymerase inhibitor RO5855 (Mericitabine Parent) and Ribavirin in combination.

Authors:  H Ma; S Le Pogam; S Fletcher; F Hinojosa-Kirschenbaum; H Javanbakht; J-M Yan; W-R Jiang; N Inocencio; K Klumpp; I Nájera
Journal:  Antimicrob Agents Chemother       Date:  2014-02-18       Impact factor: 5.191

10.  The role of nucleoside transporters in the erythrocyte disposition and oral absorption of ribavirin in the wild-type and equilibrative nucleoside transporter 1-/- mice.

Authors:  Christopher J Endres; Aaron M Moss; Rajgopal Govindarajan; Doo-Sup Choi; Jashvant D Unadkat
Journal:  J Pharmacol Exp Ther       Date:  2009-07-14       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.